Ukko is at the forefront of addressing food allergies through its innovative computational protein design platform. This technology enables the company to develop therapeutics aimed at modulating the immune system of individuals with food allergies without triggering adverse allergic reactions. By creating a clinically validated map of the molecular interactions between allergens and the immune system, Ukko unlocks essential insights into the biological mechanisms that govern human-food interactions. This foundational knowledge is critical for understanding how to effectively treat and manage food allergies.

Utilizing an AI micro-engineering platform, Ukko designs modified versions of allergens that do not provoke an allergic response while simultaneously re-educating the immune system to tolerate these allergens. This novel approach represents a significant shift in allergy treatment, moving away from traditional methods and offering a potential pathway to improve the quality of life for millions affected by food allergies. Through this advanced technology, Ukko aims to provide effective solutions that address the growing prevalence and impact of food allergies in society.

Israel

Ukko is improving the lives of millions that suffer from food allergies and disorders. We are using cutting edge technologies in immunology, computational biology, and plant science to develop a new approach. We have offices in Tel Aviv, Israel and Palo Alto, California.

Ukko

Company Details